$5.30
▲ +0.2% Today
as of Jul 22, 16:55 ET
Last 30 days
Recent Press Releases & News
Is Oncology Institute (TOI) One of the Best Future Stocks to Buy Under $10?
The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity
Why Oncology Institute’s (TOI) Analyst Upgrades Put Its Community Cancer Care Growth Story in Focus
Overview
52-week range
$2.02
$5.17
100% of range
Avg surprise (last 2)
+32.1%
Avg reaction (last 2)
-1.7%
50% positive
Latest IV / EM
95%
EM ±21.7% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.02 | $-0.07 | +71.4% | +88.9% | +7.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.14 | — | — | — | — | financials |
| Wed Aug 13, 2025 | Jun/2025 | $-0.15 | $-0.14 | -7.1% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.18 | — | — | — | -10.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.18 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.17 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.22 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.19 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.19 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 12, 2026 | Jun/2026 | OTHER | -$0.06 | -$0.15 | +60.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $147M | — | $137M | $120M | $104M | — | $100M | $99M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-7M | — | $-8M | $-11M | $-10M | — | $-14M | $-16M |
| Net income | $-2M | — | $-17M | $-17M | $-20M | — | $-16M | $-15M |
| EPS (diluted) | $-0.02 | — | $-0.14 | $-0.15 | $-0.21 | — | $-0.18 | $-0.17 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Inventory | $24M | $17M | $19M | $16M | $12M | $10M | $10M | $11M |
| Total current assets | $117M | $113M | $110M | $105M | $107M | $112M | $116M | $116M |
| Total assets | $168M | $165M | $164M | $160M | $164M | $173M | $179M | $180M |
| Long-term debt | $79M | $77M | $76M | $75M | $74M | $93M | $92M | $90M |
| Total liabilities | $185M | $180M | $176M | $169M | $159M | $169M | $164M | $150M |
| Total equity | $-16M | $-16M | $-12M | $-9M | $5M | $4M | $15M | $29M |